Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-fu and interferon-alpha-2b (Q33489279)

27 July 2017

title

Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b (English)

1 reference

27 July 2017

Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-fu and interferon-alpha-2b (English)

1 reference

Crossref

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

23 August 2024

main subject

hepatocellular carcinoma

1 reference

Y. Z. Patt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7691392

23 August 2024

B. Yoffe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7691392

23 August 2024

C. Charnsangavej

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7691392

23 August 2024

R. Pazdur

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7691392

23 August 2024

H. Fischer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7691392

23 August 2024

K. Cleary

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7691392

23 August 2024

M. Roh

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7691392

23 August 2024

R. Smith

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7691392

23 August 2024

C. A. Noonan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7691392

23 August 2024

B. Levin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7691392

23 August 2024

language of work or name

English

0 references

publication date

1 November 1993

1 reference

full work available at URL

27 July 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2819931101%2972%3A9%3C2574%3A%3AAID-CNCR2820720911%3E3.0.CO%3B2-L

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7691392

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

23 August 2024

1 reference

Crossref

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

23 August 2024

1 reference

Crossref

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

23 August 2024

1 reference

27 July 2017

1 reference

27 July 2017

1 reference

27 July 2017

page(s)

2574-2582

1 reference

Chemotherapy for advanced hepatocellular carcinoma Adriamycin versus quadruple chemotherapy

27 July 2017

cites work

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Primary liver cancer. An Eastern Cooperative Oncology Group Trial

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma. The Gastrointestinal Tumor Study Group

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Multimodality cisplatin treatment in nonresectable alpha-fetoprotein-positive hepatoma

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Chemoembolization for hepatocellular carcinoma

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Internal radiation therapy of hepatic cancer

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Interferon effects upon fluorouracil metabolism by HL-60 cells

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity.

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Nonparametric Estimation from Incomplete Observations

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

A generalized Wilcoxon test for comparing arbitrarily singly-censored samples

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

23 August 2024

1 reference

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

https://api.crossref.org/works/10.1002/1097-0142(19931101)72:9%3C2574::AID-CNCR2820720911%3E3.0.CO;2-L

23 August 2024

Identifiers

10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L

1 reference

27 July 2017

1 reference